Elite Pharmaceuticals Inc Revenue Growth Rates (ELTP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Elite Pharmaceuticals Inc   (ELTP)
 

ELTP's Revenue Growth by Quarter and Year

Elite Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ELTP/growth
https://api.csimarket.com/api/v1/companies/ELTP/fundamentals
https://api.csimarket.com/api/v1/companies/ELTP/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ELTP Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 40.08
1st Quarter June 32.36
FY 72.44

ELTPs Annual Revenue
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2026 $ 148.87 millions
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 83.09 millions
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 56.36 millions
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 33.59 millions
Elite Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 31.80 millions




ELTP Revenue second quarter 2026 Y/Y Growth Comment
Elite Pharmaceuticals Inc reported Revenue increase of 11.12% year on year in the second quarter 2026, to $ 40.08 millions, this is lower than Elite Pharmaceuticals Inc 's recent average Revenue rise of 45.8%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 173 other companies have achieved higher Revenue growth. While Elite Pharmaceuticals Inc ' s Revenue growth of 11.12% ranks overall at the positon no. 3844 in the second quarter 2026.


ELTP Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 11.12 %
1st Quarter June -17.51 %
FY   -

Financial Statements
Elite Pharmaceuticals Inc 's second quarter 2026 Revenue $ 40.08 millions ELTP's Income Statement
Elite Pharmaceuticals Inc 's second quarter 2025 Revenue $ 36.07 millions Quarterly ELTP's Income Statement


ELTP Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 23.86 %
1st Quarter June -20.59 %
FY (Year on Year)   -


Back to ELTP Growth rate Comparisons >> Back to ELTP Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #174
Healthcare Sector #504
Overall #3844

Revenue Y/Y Growth Statistics
High Average Low
320.99 % 45.8 % -74.01 %
(Mar 31 2016)   (Sep 30 2017)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #174
Healthcare Sector #504
Overall #3844
Revenue Y/Y Growth Statistics
High Average Low
320.99 % 45.8 % -74.01 %
(Mar 31 2016)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Elite Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
228.07 % 15.69 % -72.31 %
(Mar 31 2013)  


ELTP's II. Quarter Q/Q Revenue Comment
Elite Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 23.86%, to $ 40.08 millions, from $32.36 millions in the first quarter.
ELTP is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 186 other companies have achieved higher Revenue quarter on quarter growth. While Elite Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3613.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #187
Healthcare Sector #528
Overall #3613
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #187
Healthcare Sector #528
Overall #3613
Revenue Q/Q Growth Statistics
High Average Low
228.07 % 15.69 % -72.31 %
(Mar 31 2013)  


ELTP's II. Quarter Q/Q Revenue Comment
Elite Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 23.86%, to $ 40.08 millions, from $32.36 millions in the first quarter.
ELTP is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 186 other companies have achieved higher Revenue quarter on quarter growth. While Elite Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3613.


Elite Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 144.14
Y / Y Revenue Growth (TTM) 18.42 %
Year on Year Revenue Growth Overall Ranking # 359
Seqeuential Revenue Change (TTM) 2.86 %
Seq. Revenue Growth (TTM) Overall Ranking # 779


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Elite Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 144 millions, company would post below average annual Revenue growth of 2.86% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Elite Pharmaceuticals Inc 's Revenue growth from the 32.36% growth in Jun 30 2026.

In the Healthcare sector 88 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 359, from total ranking in previous quarter at 396.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 89
Overall # 359

Revenue TTM Y/Y Growth Statistics
High Average Low
242.28 %
 42.12 %
-47.5 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 67
Sector # 157
S&P 500 # 779
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Elite Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 144 millions, company would post below average annual Revenue growth of -47.5% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Elite Pharmaceuticals Inc 's Revenue growth from the 32.36% growth in Jun 30 2026.

In the Healthcare sector 88 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 359, from total ranking in previous quarter at 396.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 67
Healthcare Sector # 89
Overall # 359

Revenue TTM Y/Y Growth Statistics
High Average Low
242.28 %
42.12 %
-47.5 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 67
Sector # 157
S&P 500 # 779




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ELTP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions


About Elite Pharmaceuticals Inc Revenue Growth Rates (ELTP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Elite Pharmaceuticals Inc Nv (CIK 1053369).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-051384
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Elite Pharmaceuticals Inc Nv’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.